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Intravascular Stenting 
for Prevention of 
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the Magic Bullet* 
FRANK LITVACK, MD, FACC 
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Restenosis persists as the single greatest limitation of percu- 
taneous transluminal coronary angioplasty and, in terms of 
efficacy and cost effectiveness, it may ultimately represent 
the single greatest limitation to multivessel, multilesion 
balloon angioplasty. The problem of restenosis within suc- 
cessfully dilated coronary vein grafts is particularly trouble- 
some. Despite acceptable short-term rates of successful vein 
graft dilation, stenosis recurs in 30% to 60% of patients 
depending on site of dilation within the graft (l-3). To date, 
no medical or physical intervention has demonstrated defin- 
itive efficacy in preventing restenosis. Randomized trials of 
aspirin, warfarin and dipyridamole have not shown signifi- 
cant effects (4,5). Investigators (6-10) are currently endeav- 
oring to physically cut out, burn, vaporize and grind the 
plaque to a pulp. 
In this issue of the Journal, Urban et al. (11) report their 
early experience with the use of intravascular stenting to 
manage stenosis in aortocoronary vein bypass grafts. Inter- 
est in stenting with use of tubular coiled wire devices dates 
back to the first report by Dotter (12) in 1969. Placed into the 
femoral arteries of dogs, these cylindrical open-ended steel 
coils exhibited respectable long-term patency. Despite these 
encouraging results, they were not used clinically because 
significant narrowing occurred within the lumen over time. 
Subsequently, other investigators (13-15) designed and de- 
ployed a variety of metallic stents differing in type of metal 
used, technique of deployment, arrangement of the metallic 
components and amount of metallic surface exposed to the 
vascular lumen. Such stents have two potential roles in 
coronary arteries. First, they may be useful in controlling 
arterial dissection after balloon angioplasty or other coro- 
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nary intervention. Second, they may ameliorate restenosis. 
It is the latter indication that is addressed in the study by 
Urban et al. (11). 
Present study. Thirteen patients with angina underwent 
percutaneous implantation of one or more stents in 14 
stenosed vein grafts. Stent deployment was technically 
possible in all cases, and short-term complications directly 
related to manipulation of the grafts included one case of 
distal embolization and one episode of ventricular fibrilla- 
tion. The study by Urban et al. (11) represents interesting, 
potentially significant, original work, but it is subject to 
important limitations. The total number of patients studied is 
small and the follow-up period ranged from 2 to 26 months. 
Only 10 patients (77%) had follow-up angiography. Because 
of the pilot nature of the study and the relatively early 
generation of stent design used, the study was performed in 
neither a controlled nor a randomized fashion. So long as 
one keeps these limitations in mind, important observations 
may be extracted from the data and new objectives defined. 
The safety of this procedure appears within acceptable 
limits for a coronary intervention. There were no deaths 
directly attributable to the procedure and no myocardial 
infarctions or abrupt thrombotic occlusions. Of significance, 
the patients were maintained on an extravagant regimen of 
antiplatelet and antithrombotic agents. The hazard of such 
an approach relative to systemic bleeding complications 
needs to be evaluated. 
With respect to amelioration of restenosis, the data 
presented in this study are not conclusive. Seven patients 
(54%) remained asymptomatic or were in improved condi- 
tion without further intervention during the follow-up pe- 
riod. One patient died from progressive congestive heart 
failure 7 months after stent implantation. Two patients (15%) 
developed restenosis within the body of the stent. One of 
these was treated by balloon angioplasty alone and remained 
asymptomatic. The second of these patients epitomizes the 
pernicious nature of restenosis. After he underwent success- 
ful balloon angioplasty within the stent, angina subsequently 
returned. Successful percutaneous atherectomy was per- 
formed but the graft restenosed shortly thereafter. After a 
second successful atherectomy, the patient again developed 
angina. Because of a relative contraindication to a third 
bypass operation, we recently performed, out of despera- 
tion, percutaneous excimer laser angioplasty on the patient’s 
vein graft that has been initially successful. This patient 
makes us wonder whether any mechanical intervention will 
be the solution. Three other patients in the Urban study (11) 
required further angioplasty with stent implantation for a 
new stenosis proximal to the stent site in the same vein graft. 
Even if one presumes that the patient who died succumbed 
secondary to factors unrelated to graft restenosis, then 5 
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(38%) of 13 patients did develop restenosis within the treated 
graft. This may not represent significant diminution relative 
to conventional therapies alone. Whether the stents initiated 
local rheologic disturbances responsible for the appearance 
of new proximal stenoses is unknown and will require 
further study. 
Postangioplasty restenosis. The problem of restenosis af- 
ter angioplasty is highly complex and the pathogenesis is 
incompletely understood. Important but not yet fully defined 
variables include local hemodynamic and rheologic events, 
platelets, platelet-derived growth factors and other mitogens 
and the response of smooth muscle cells to vascular injury. 
It is probably naive to assume, in the absence of a well 
described pathophysiologic scheme, that any one interven- 
tion will solve the restenosis problem. The most important 
conclusion one may draw from the study of Urban et al. (1 I) 
is that intravascular stenting is worthy of inclusion among 
the other medical and mechanical modalities being used in 
the multiple front war against restenosis. Further research is 
required. Differences in stent design may modify endothelial 
and smooth muscle response. If pilot, prospective studies 
continue to produce encouraging observations, then a ran- 
domized trial or registry will become necessary. Dr. Paul 
Ehrlich required 606 attempts before he discovered his 
“magic bullet” therapy for syphilis. One only hopes that we 
cardiologists may be more expeditious in the search for our 
magic bullet. 
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